Cathepsin E drives colorectal cancer progression and immune evasion via ZNF326 ADP-ribosylation and TGF-β/SMAD activation - PubMed
2 hours ago
- #Colorectal cancer
- #ADP-ribosylation
- #Immune evasion
- Cathepsin E (CTSE) promotes colorectal cancer (CRC) progression and immune evasion.
- CTSE stabilizes ZNF326 through ADP-ribosylation at glutamate 338, activating the TGF-β/SMAD pathway.
- CTSE enhances PD-L1/PD-1 interactions, reducing CD8+ T cell-mediated tumor cell killing.
- ZNF326 knockdown or TGF-β/SMAD pathway inhibition abolishes CTSE's tumor-promoting effects.
- CTSE is a potential therapeutic target for CRC, especially in combination with PD-1/PD-L1 inhibitors.